Werewolf Therapeutics, Inc. (HOWL): Capital Expenditures
$0
Year ended 2025-12-31
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $0 | -100.0% | 2026-03-27, From 2025-01-01 |
| 2024-12-31 | $254.0K | -67.0% | 2026-03-27, From 2024-01-01 |
| 2023-12-31 | $769.0K | -78.7% | 2025-03-11, From 2023-01-01 |
| 2022-12-31 | $3.61M | +625.1% | 2024-03-07, From 2022-01-01 |
| 2021-12-31 | $498.0K | -11.1% | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | $560.0K | n/a | 2022-03-24, From 2020-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Werewolf Therapeutics, Inc. (HOWL) | 2025-12-31 | $0 | -100.0% |
| Context Therapeutics Inc. (CNTX) | 2025-12-31 | $33.9K | +364.0% |
| Corvus Pharmaceuticals, Inc. (CRVS) | 2025-12-31 | $174.0K | n/a |
| Inovio Pharmaceuticals, Inc. (INO) | 2025-12-31 | $285.7K | -41.4% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $97.9K | +47.3% |
| Rallybio Corp (RLYB) | 2024-12-31 | $0 | -100.0% |
| OnKure Therapeutics, Inc. (OKUR) | 2025-12-31 | $46.0K | -11.5% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $3.57M | +160.5% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $0 | -100.0% |
Compare HOWL, CNTX, CRVS, INO side by side · Screen every company in Pharmaceutical Preparations ↗